智通财经APP获悉，据港交所2月13日披露，深圳易慕峰生物科技股份有限公司(简称：易慕峰生物)向港 交所主板递交上市申请，华泰国际为其独家保荐人。 | : [编纂]股H股(視乎[编纂] | 编纂]的[編纂]數目 | 行使與否而定) | | | | | --- | --- | --- | --- | --- | --- | | [編纂]數目 | . | [编纂]股H股(可予[編纂]) | [編纂]數目 | .. | [編纂]股H股(可予[編纂]及視乎 | | [編纂]行使與否而定) | : | 最高[編纂] | 每股H股[編纂]港元,另加1.0%經紀 | | | | 佣金、0.0027%證監會交易徵費、 | 0.00015%會財局交易徵費及 | | | | | | 0.00565%聯交所交易費(須於[編纂] | 時以港元繳足,多繳款項可予退還) | | | | | | .. | 面值 | 每股H股[編纂] | : [0] | [編纂] | | | your sites (ra shop 1 - 1 = 1 | | | | | | 公司简介 据招股书，易慕峰生物是一家全球领先的创新型细胞治疗公司。公司的核心产品 ...

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was approximately $12.5 billion, flat year-over-year, while the growth portfolio revenue increased by 15% to $7.4 billion, representing nearly 60% of total revenue [12][13] - For the full year, the growth portfolio grew 17%, offsetting a decline of roughly $4 billion in revenue from the legacy portfolio [4][5] - Adjusted diluted earnings per share for Q4 were $1.26, and for the full year, it was $6.15, both including a net charge related to in-process R&D and licensing income [18][19] Business Line Data and Key Metrics Changes - Opdivo revenue grew 7% to nearly $2.7 billion in Q4, driven by new indications and share growth in first-line non-small cell lung cancer [14] - Reblozyl delivered 21% growth, reflecting solid uptake across first- and second-line MDS-associated anemia patients [15] - Breyanzi's revenue increased by 47% in Q4, driven by strong demand across its approved indications [15] - Eliquis revenue was nearly $3.5 billion in Q4, up 6%, supported by demand growth and market share gains [16] - Camzyos revenue grew 57% to $353 million in Q4, benefiting from global demand growth [16] Market Data and Key Metrics Changes - The company anticipates a revenue decline for the legacy portfolio of 12%-16% in 2026 due to ongoing loss of exclusivity impacts [11] - Eliquis is projected to grow 10%-15% in 2026, driven by global demand growth and a recent price reduction [11] Company Strategy and Development Direction - The company aims to deliver industry-leading sustainable growth into the 2030s and beyond, focusing on executing its growth strategy and advancing its pipeline [10][22] - The company plans to report top-line registrational data for six potential new products in 2026, with more than 30 meaningful launch opportunities expected by 2030 [8][9] - The company is committed to maintaining a strong cost-savings initiative, targeting an additional $1 billion in savings over 2026 and 2027 [17][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver long-term value for patients and shareholders, highlighting a strong performance in 2025 [22] - The company is optimistic about the upcoming data readouts and the potential for new medicines to enhance its growth profile [8][9] Other Important Information - The company has a strong financial position with approximately $11 billion in cash equivalents and marketable securities as of December 31, 2025 [18] - The effective tax rate for Q4 was 22.1%, reflecting a one-time non-tax deductible in-process R&D charge related to the Orbital acquisition [17] Q&A Session Summary Question: Insights on pivotal catalysts and growth areas - Management highlighted the excitement around upcoming data readouts for six products and the potential for over 10 phase III data readouts in 2026, emphasizing the growth of the CELMoD program and the potential of Milvexian in AFib [26][27] Question: Eliquis dynamics and business development priorities - Eliquis is expected to continue strong performance in 2026, with a 75% market share in the U.S. Management is focused on deepening presence in existing therapeutic areas while remaining opportunistic in business development [35][36] Question: Updates on Milvexian and metabolic opportunities - The Milvexian study is progressing well, with a focus on demonstrating non-inferiority to Eliquis. Management is also monitoring the metabolic space but prioritizing existing therapeutic areas for business development [41][42] Question: Admilparant's hypotension risk and generic competition - Management addressed the manageable hypotension risk associated with Admilparant and discussed expectations for generic competition for Eliquis and Orencia, with significant impacts anticipated in 2026 and 2027 [82][83]

Core Viewpoint - The study demonstrates that CXCR4-modified CAR-T cells enhance the efficacy of treatment for B-cell malignancies by improving tumor tracking and bone marrow homing capabilities, showing promising results in initial human trials [2][3][8]. Group 1: Research Findings - The research developed CAR-T cells with overexpressed CXCR4, which significantly improved their ability to track tumors and home to the bone marrow, thereby enhancing treatment outcomes for B-cell malignancies [3][5]. - The study found that during CAR-T cell preparation, the expression of CXCR4 on the cell surface was significantly downregulated after lentiviral-mediated gene transfer, impairing the chemotactic response to CXCL12. In contrast, enhancing CXCR4 expression (CXCR4 hi) markedly improved tumor tracking and bone marrow homing in vivo [6]. - In models of localized and systemic spread of B-cell lymphoma and multiple myeloma, CXCR4 hi CAR-T cells demonstrated superior therapeutic effects compared to second-generation CAR-T cells, even at a quarter of the infusion dose [6]. Group 2: Clinical Trials - Based on the findings, the research team initiated the first human clinical trial of autologous CXCR4 hi CD19 CAR-T cells for patients with relapsed/refractory B-cell lymphoma (NCT04684472), which showed promising results with complete and partial remissions observed in the low-dose group within the first month post-infusion [6][8]. - CXCR4 hi CD19 CAR-T cells exhibited strong tumor-clearing capabilities in patients with relapsed/refractory B-cell lymphoma without severe toxic side effects, indicating the potential of CXCR4 modification as an effective strategy to enhance CAR-T cell therapy for B-cell malignancies [8].

Core Viewpoint - The articles highlight the potential of CAR-T cell therapies targeting tumor-associated macrophages (TAM) expressing IL-12, which can reshape the tumor microenvironment and stimulate anti-tumor immune responses against solid tumors, independent of tumor antigens [3][7][12]. Group 1: Research Findings - The study from Mount Sinai Icahn School of Medicine developed IL-12 armored CAR-T cells targeting FOLR2 or TREM2 to eliminate pro-tumor TAMs, significantly improving survival rates in metastatic ovarian and lung cancer models [5][10]. - The CAR-T therapy demonstrated efficacy at low cell doses without the need for lymphocyte depletion, primarily localized to tumor sites with no significant side effects [5][10]. - Spatial transcriptomics indicated that the CAR-T cells could continue to reshape the tumor microenvironment even after their numbers naturally declined post-treatment, leading to the expansion of immune-stimulating macrophages and endogenous tumor-specific cytotoxic T cells [5][10]. Group 2: Mechanism and Strategy - The research introduced a CAR targeting TREM2+ immunosuppressive TAMs, showing strong in vitro activity and significant anti-tumor effects in vivo [10]. - A synthetic CAR-responsive biosensor was incorporated to enhance local IL-12 secretion within the tumor, further improving the therapeutic effect [10]. - The IL-12 armored hTREM2 CAR-T cells reprogrammed the tumor microenvironment and lymph nodes, clearing TREM2+ TAMs and enhancing the infiltration and activation of T cells and natural killer (NK) cells, leading to tumor regression without systemic toxicity [10][12].

Core Viewpoint - The sales of CAR-T cell therapy Carvykti (西达基奥仑赛) have significantly increased, but the stock price of Legend Biotech (传奇生物) has declined following the earnings report from Johnson & Johnson (强生) [1] Group 1: Financial Performance - Johnson & Johnson reported a total revenue of $94.193 billion for 2025, a year-on-year increase of 6% [1] - Carvykti generated $1.887 billion in revenue for 2025, representing a 95.95% increase compared to $963 million in 2024 [1] - In Q4 2025, Carvykti's sales reached $555 million, a 65.8% year-on-year increase, but only a 5.9% quarter-on-quarter growth [1] Group 2: Market Position and Product Development - Carvykti is positioned as a one-time therapy for relapsed or refractory multiple myeloma and has been approved in the U.S., EU, and Japan [3] - The product was priced at $465,000 per dose in the U.S., which is approximately three times the price of other domestic CAR-T products [3] - Legend Biotech aims to achieve profitability in 2026 by expanding Carvykti's application globally and increasing its use in community healthcare settings [4] Group 3: Production and Clinical Trials - Legend Biotech has completed the expansion of its production facility in Raritan, which is the largest CAR-T production base in the U.S., capable of supporting the treatment of up to 10,000 patients annually [4] - The company has initiated a Phase 3 clinical trial (CARTITUDE-6) for new indications targeting newly diagnosed multiple myeloma patients [4] Group 4: Market Challenges and Pricing - The commercialization of Carvykti in China lagged behind the U.S. market by two years, with approval granted in August 2024 [7] - The pricing strategy for the Chinese market has not yet been disclosed, and the product has not participated in national health insurance negotiations [7] - The high costs associated with CAR-T therapies pose challenges for accessibility, despite ongoing efforts to explore diverse payment models [8][9]

Core Insights - WuXi AppTec's JWCAR201, an autologous CAR-T product targeting CD19/CD20, shows promising initial results in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [1][2] Group 1: Study Overview - The study is a single-arm, open-label, multi-center, dose-exploration IIT research conducted in China, evaluating JWCAR201's safety and preliminary efficacy [1] - The initial dose was set at 25×10^6 CAR+ T cells, with exploration at three dose levels: 25×10^6, 50×10^6, and 100×10^6 CAR+ T cells [1] Group 2: Patient Demographics - A total of 7 patients were infused, with a median age of 56 years (range: 42 to 72 years), and 42.9% were male [2] - The patient cohort exhibited high-risk characteristics, including 85.7% with DLBCL-NOS, 57.1% with non-GCB subtype, and 57.1% having an International Prognostic Index (IPI) score of ≥3 [2] Group 3: Efficacy Results - The overall response rate (ORR) reached 100% (7/7), with a complete response rate (CRR) of 85.7% (6/7) [2] - All patients except one maintained their response for at least 180 days, indicating significant efficacy [2] Group 4: Safety Profile - Among the 7 patients, 42.9% experienced grade 1 cytokine release syndrome (CRS), and 14.3% had grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) [3] - No high-grade CRS or ICANS were reported, and no dose-limiting toxicities (DLT) occurred, suggesting a manageable safety profile [3] Group 5: Future Prospects - The company believes JWCAR201 demonstrates excellent efficacy and good overall safety, with manageable adverse reactions, indicating strong potential for advancement to the IND stage [3]

Core Insights - The article discusses the transformative potential of in vivo CAR-T cell therapy, which aims to overcome the limitations of traditional CAR-T therapies by generating CAR-T cells directly within the patient, thus eliminating complex manufacturing and logistics challenges [2][3][6]. Group 1: In Vivo CAR-T Technology - In vivo CAR-T technology leverages advancements in virology, RNA therapeutics, and nanomedicine to deliver genetic material encoding CAR into endogenous T cells, enhancing clinical efficacy and simplifying the treatment process [2][3][9]. - The technology aims to expand the applicability of CAR-T therapies beyond hematological malignancies to include autoimmune diseases like systemic lupus erythematosus [3][7]. Group 2: Clinical Development and Platforms - The article highlights two main in vivo CAR platforms: engineered viral vectors (such as lentiviruses) that integrate payloads into the host genome, and lipid nanoparticles (LNPs) that enable transient expression of the payload within host cells [9][11]. - Several companies are developing in vivo CAR-T therapies, with various targeting mechanisms and therapeutic payloads aimed at treating conditions like B cell malignancies and solid tumors [10][11]. Group 3: Future Directions and Challenges - The review emphasizes the need for innovation in delivery and engineering technologies to fully realize the potential of CAR-T therapies, addressing current limitations in accessibility and clinical performance [7][15]. - The transition from ex vivo to in vivo CAR-T therapies is expected to redefine the scalability and accessibility of immunotherapies, significantly reducing production costs and enhancing the socio-economic impact of these life-saving treatments [23].

Core Viewpoint - 科济药业 is actively repurchasing its shares to enhance shareholder value while continuing to develop innovative CAR-T therapies for unmet clinical needs [1][2] Group 1: Share Repurchase Activity - On November 6, 科济药业 announced the repurchase of 1.734 million shares at a price range of HKD 14.350 to HKD 15.8, totaling HKD 26.3078 million [1] - In the past month, the company has conducted three repurchase activities, acquiring a total of 2.189 million shares for a cumulative amount of HKD 33.9758 million [1] - The company has a repurchase plan allowing it to buy back up to 1% of its total issued shares in the open market [1] Group 2: Company Overview and Product Pipeline - 科济药业 is a biopharmaceutical company focused on developing innovative CAR-T cell therapies to address unmet clinical needs, including hematologic malignancies, solid tumors, and autoimmune diseases [1] - The company has 10 CAR-T pipeline products, including 4 autologous CAR-T and 6 universal CAR-T, all of which are self-developed with global rights [1] - The all-human BCMA autologous CAR-T product,赛恺泽, has been approved for marketing in China, while the Claudin18.2 autologous humanized CAR-T product,舒瑞基奥仑赛, is the first CAR-T product for solid tumors to submit a new drug application globally [1] Group 3: Recent R&D Achievements - On November 3, 科济药业 announced new clinical data for its universal CAR-T products, CT0596 and CT1190B, showing promising safety and efficacy signals for treating relapsed/refractory multiple myeloma and non-Hodgkin lymphoma, respectively [2] - As of June 30, 2026, the company reported cash and cash equivalents exceeding HKD 1.26 billion, indicating a strong financial position to support ongoing operations and share repurchase plans [2] - The management expressed commitment to maintaining the share repurchase program, adjusting it based on market conditions to further protect shareholder interests [2]

Core Viewpoint - Azalea Therapeutics, co-founded by Nobel laureate Jennifer Doudna, is entering the competitive in vivo CAR-T field with a focus on innovative gene therapy solutions and a new delivery technology platform [2][3]. Funding and Development Plans - On November 4, 2025, Azalea announced a funding round of $82 million to advance an in vivo CAR-T cell therapy for B-cell malignancies into clinical stages within the next 12-18 months [2]. - The company aims to further develop its novel delivery technology platform [2]. Technology and Innovation - Azalea's core asset is the Enveloped Delivery Vehicle (EDV), a delivery technology developed in Doudna's lab, which was published in Nature Biotechnology in January 2024 [3]. - The EDV utilizes a modified vesicular stomatitis virus glycoprotein (VSVGmut) paired with antibody-derived single-chain variable fragments (scFv) to package Cas9 ribonucleoprotein complexes for targeted genome editing [5][7]. Advantages of EDV - Unlike traditional delivery systems, EDV allows for predictable antibody-antigen interactions, enabling selective and instantaneous delivery of genome editing components to target cells [7]. - In mixed cell populations, Cas9-EDV preferentially edits the genome in target cells without off-target effects in liver cells, establishing a programmable delivery strategy with broad therapeutic potential [7]. Founding Team and Expertise - The founding team includes Michael Fischbach and Justin Eyquem, with Eyquem contributing a second delivery vehicle for in vivo CAR-T therapy [9]. - Eyquem's previous research demonstrated that integrating CAR into the TRAC gene locus reduces potential oncogenic risks and enhances anti-tumor activity [9]. Upcoming Presentations and Industry Context - Azalea plans to present a series of proof-of-concept data from tumor mouse models at the upcoming ASGCT conference, with experiments in primate models also underway [10]. - The in vivo CAR-T sector has seen significant activity in 2023, with multiple acquisitions and advancements from major companies, indicating a rapidly evolving landscape [11][12][13][14].

Core Insights - Kintor Pharmaceutical (02171.HK) announced clinical data for its universal BCMA CAR-T product CT0596 and universal CD19/CD20 CAR-T product CT1190B, both showing promising safety and efficacy signals for treating relapsed/refractory multiple myeloma (R/R MM) and non-Hodgkin lymphoma (R/R NHL) respectively [1][2] Group 1: Product Development - CT0596 is a universal CAR-T cell therapy targeting BCMA, currently undergoing investigator-initiated clinical trials for R/R MM and plasma cell leukemia (PCL), with plans to submit an IND application in the second half of 2025 [1] - CT1190B targets CD19/CD20 and is involved in clinical trials for treating relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc) [2] Group 2: Company Overview - Kintor Pharmaceutical is a biopharmaceutical company focused on developing innovative CAR-T cell therapies to address unmet clinical needs, including hematologic malignancies, solid tumors, and autoimmune diseases [2] - The company has established end-to-end capabilities in CAR-T cell research and development, from target discovery to commercial-scale production, positioning itself as a leading global player in CAR-T therapy [2] - Kintor currently has 10 CAR-T pipeline products, including 4 autologous CAR-T and 6 universal CAR-T, all of which are self-developed with global rights [2]